Benitec Biopharma Inc. (BNTC)
| Market Cap | 21.20M |
| Revenue (ttm) | 21,000 |
| Net Income (ttm) | n/a |
| Shares Out | 4.82M |
| EPS (ttm) | -4.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 18 |
| Last Price | $4.45 |
| Previous Close | $4.25 |
| Change ($) | 0.20 |
| Change (%) | 4.71% |
| Day's Open | 4.26 |
| Day's Range | 4.15 - 4.47 |
| Day's Volume | 109,575 |
| 52-Week Range | 2.30 - 12.52 |
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...
HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...
Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gain...
Dolphin Entertainment Inc (NASDAQ: DLPN) shares are trading 150% higher after the company announced it launched a non-fungible token (NFT) creation and marketing division. Dolphin Entertainment produces...
What will the stock market do today? All eyes are on President Joe Biden and his spending plan, as well as Covid-19 vaccine news.
Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company. The post BNTC Stock: One Big Investor Has Benitec Biopharma Shar...
The shares of Benitec Biopharma Inc (NASDAQ: BNTC) are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday. What Happened: Benitec shares had closed at $3.19 on Monday.
Benitec Biopharma's Gene Therapy For Rare Muscle Disorder Shows Encouraging Action In Animal Studies
Benitec Biopharma Inc (NASDAQ: BNTC) reports an interim analysis of the BB-301 Pilot Dosing study conducted in large animal subjects. BB-301 a genetic medicine directly injected into the pharyngeal musc...
HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December 9, 2020 at...
HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...
HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...
HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...
HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.
HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the pro...
Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.
About BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
| Industry Biotechnology | Founded 1995 |
| Stock Exchange NASDAQ | Ticker Symbol BNTC |